{"id":"W2603868241","doi":"10.1200/jco.2012.30.15_suppl.e14706","title":"Multistage phase II design for mixed tumor response and time-to-event endpoints: An application for screening new drugs in hepatocellular carcinoma (HCC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Aegera Therapeutics (Canada)","funders":"","keywords":"Medicine; Sorafenib; Clinical endpoint; Surrogate endpoint; Oncology; Internal medicine; Early stopping; Progression-free survival; Hepatocellular carcinoma; Hazard ratio; Phases of clinical research; Randomized controlled trial; Clinical trial; Overall survival; Confidence interval; Machine learning","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.1235146,0.003281036,0.003582649,0.001497514,0.0008545516,0.001360537,0.002230392,0.003526474,0.008018697],"category_scores_gemma":[0.07464936,0.001442382,0.004633593,0.0008725131,0.002657301,0.001446154,0.002402174,0.004700306,0.0007147224],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00147584,"about_ca_system_score_gemma":0.002929344,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004306891,"about_ca_topic_score_gemma":0.0005391116,"domain_scores_codex":[0.9122051,0.08075076,0.001623566,0.002330102,0.002029568,0.001060966],"domain_scores_gemma":[0.945231,0.04282239,0.004179555,0.004032238,0.002685855,0.001048989],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.1632766,0.007384486,0.01618017,0.00428257,0.005710301,0.0010807,0.001787934,0.3825808,0.01261801,0.1666967,0.008573736,0.229828],"study_design_scores_gemma":[0.03945266,0.04173042,0.003424372,0.0002738432,0.001370137,0.0002327566,0.00009610224,0.84892,0.005766426,0.04793729,0.0105506,0.0002454078],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","genre_codex":"methods","genre_gemma":"methods","genre_scores_codex":[0.06493376,0.0006539177,0.8850819,0.0006171708,0.00076732,0.04496311,0.000521947,0.0007206188,0.001740243],"genre_scores_gemma":[0.2464437,0.0002341288,0.6447024,0.0008025225,0.0001655632,0.1044578,0.0005079258,0.0001018296,0.002584096],"genre_candidate":"methods","genre_consensus":"methods","teacher_disagreement_score":0.1235146,"threshold_uncertainty_score":0.6532155,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.590656214930436,"score_gpt":0.6152416354378769,"score_spread":0.02458542050744095,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}